Oppenheimer Reiterates Outperform on Crinetics Pharmaceuticals, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell reiterates an Outperform rating on Crinetics Pharmaceuticals (CRNX) and raises the price target from $48 to $54.
March 13, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell reiterates an Outperform rating on Crinetics Pharmaceuticals and raises the price target from $48 to $54.
The reiteration of an Outperform rating combined with an increased price target from $48 to $54 by a reputable analyst suggests a positive outlook on CRNX's stock performance in the short term. This could lead to increased investor confidence and potentially drive the stock price up.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100